Search Within

Lymphoma

Formats
  1. Meeting Abstract (1382)
  2. Journal Article (1055)
  3. Book Section (64)
  4. Review (64)
  5. Editorial (38)
  6. Research Letter (38)
  7. Guidelines (18)
  8. Conference Paper (15)
  9. Correspondence (11)
  10. Miscellaneous (5)
  11. Book Whole (4)
Groups
  1. Center for Hematologic Malignancies (2694)
  2. Department of Medicine (2694)
  3. Hematologic Malignancies, Division of (2694)
  4. Population Sciences Research Program (742)
  5. Survivorship Research (654)
  6. Executive Committee, Center for Hematologic Malignancies (391)

More Groups

People
  1. Andrew Zelenetz (781)
  2. Steven Horwitz (664)
  3. Maria Palomba (443)
  4. Ariela Noy (369)
  5. David Straus (360)
  6. Alison Moskowitz (355)

More People

Years
  1. 2025 (41)
  2. 2024 (141)
  3. 2023 (180)
  4. 2022 (170)
  5. 2021 (171)
  6. 2020 (170)

More Years

Publications
  1. Blood (875)
  2. Journal of Clinical Oncology (277)
  3. Hematological Oncology (110)
  4. British Journal of Haematology (81)
  5. Leukemia and Lymphoma (81)
  6. Haematologica (71)

More Publications

Publishers
  1. American Society of Hematology (940)
  2. American Society of Clinical Oncology (293)
  3. Elsevier Inc. (187)
  4. Wiley Blackwell (174)
  5. John Wiley & Sons (96)
  6. Nature Publishing Group (93)

More Publishers

Results (2694)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The Stanford experience with utilizing the new WHO classification of cutaneous lymphomas for cutaneous B cell lymphoma
    Meeting Abstract

    Reddy, S.; Kohler, S.; Horwitz, S.; Sutherland, K.; Hoppe, R. T.; Kim, Y. H.
    Journal of Investigative Dermatology (2006)

    Fulltext@MSK | Save
  • Infectious disease associations in advanced stage, indolent lymphoma (Follicular, FL and non-follicular, nFL): Developing a lymphoma prevention strategy
    Meeting Abstract

    Portlock, C. S.; Hamlin, P. A.; Noy, A.; Palomba, M. L.; Rosenzweig, L.; Walker, D.; Corcoran, S.; Chey, W. D.; Gaydos, C. A.; Schwartz, I.; more...
    Blood (2006)

    Fulltext@MSK | Save
  • Pralatrexate (PDX) produces durable complete remissions in patients with chemotherapy resistant precursor and peripheral T-Cell lymphomas: Results of the MSKCC phase I/II experience
    Meeting Abstract

    O'Connor, O. A.; Hamlin, P. A.; Gerecitano, J.; Portlock, C. S.; Noy, A.; Moskowitz, C.; Straus, D. J.; Sarasohn, D.; Dumitrescu, O.; Pappanicholaou, J.; more...
    Blood (2006)

    Fulltext@MSK | Save
  • Early phase experience with pralatrexate (10-propargyl-10-deazaaminopterin [PRX]), a novel antifolate with high affinity for the reduced folate carrier, in patients with chemotherapy refractory lymphoproliferative malignancies
    Meeting Abstract

    O'connor, O.; Hamlin, P.; Neylon, E.; Moskowitz, C.; Portlock, C.; Noy, A.; Sirotnak, F.; Zelenetz, A.; Mould, D.; Horwitz, S.
    EJC Supplements (2006)

    Fulltext@MSK | Save
  • Phase II trial of dose-dense R-CHOP followed by risk-adapted consolidation with either ICE or ICE and ASCT, based upon the results of biopsy confirmed abnormal interim restaging PET scan, improves outcome in patients with advanced stage DLBCL
    Meeting Abstract

    Moskowitz, C.; Hamlin, P. A.; Horwitz, S. M.; Noy, A.; O'Connor, O. A.; Palomba, M. L.; Portlock, C. S.; Straus, D. J.; Lessac-Chenen, S.; Weaver, A.; more...
    Blood (2006)

    Fulltext@MSK | Save
  • FDG-PET scans as a staging study for T-cell lymphomas: High rates of positivity do not result in frequent changes in stage
    Meeting Abstract

    Horwitz, S. M.; Foss, F.; Goldfarb, S.; Molina, A.; Hamlin, P. A.; O'Connor, O. A.; Cammarata, M.; Moskowitz, C. H.; Zelenetz, A. D.
    Blood (2006)

    Fulltext@MSK | Save
  • Relapsed and refractory primary mediastinal diffuse large B-cell lymphoma: Outcome with ICE-based treatment
    Meeting Abstract

    Hamlin, P. A.; Dickson, M.; Kewalramani, T.; Horwitz, S. M.; Portlock, C. S.; Yahalom, J.; Zelenetz, A. D.; Moskowitz, C. H.
    Blood (2006)

    Fulltext@MSK | Save
  • The schedule dependent combination of bortezomib (Bor) with rituximab (R), cyclophosphamide (C) and prednisone (P) produces minimal toxicity, even at relatively high doses of proteasome inhibitor, in patients with relapsed/refractory indolent B-cell lymphomproliferative disorders
    Meeting Abstract

    Gerecitano, J.; Portlock, C.; Noy, A.; Hamlin, P.; Moskowitz, C.; Straus, D.; Horwitz, S. M.; Palomba, M. L.; Dumitrescu, O. L.; Pappanicholaou, J.; more...
    Blood (2006)

    Fulltext@MSK | Save
  • Feasibility of a self-administered geriatric assessment for cancer patients
    Meeting Abstract

    Gardes, J. H.; Zuckerman, E.; Lichtman, S. M.; Hamlin, P.; Kelly, E.; Lachs, M.; Hurria, A.
    Journal of the American Geriatrics Society (2006)

    Fulltext@MSK | Save
  • Initial therapeutic strategy in follicular lymphoma (FL): An analysis from the National LymphoCare Study (NLCS)
    Meeting Abstract

    Friedberg, J. W.; Huang, J.; Dillon, H.; Farber, C.; Feliciano, S.; Hainsworth, J.; Link, B.; Steis, R.; Vose, J.; Zelenetz, A.
    Journal of Clinical Oncology (2006)

    Fulltext@MSK | Save